FDA Grants Breakthrough Therapy Designation to Sutacimig for Rare Bleeding Disorder

FDA Grants Breakthrough Therapy Designation to Sutacimig for Rare Bleeding Disorder

By, Admin 8 March 2026

Hemab Therapeutics has received a major regulatory boost after the U.S. Food and Drug Administration granted Breakthrough Therapy Designation (BTD) to its investigational drug Sutacimig.

The therapy is being developed for the prevention of bleeding episodes in patients with Glanzmann thrombasthenia (GT), a rare and severe inherited bleeding disorder.

The designation highlights the potential of sutacimig to address a major unmet medical need, as there are currently no effective prophylactic treatments available for this condition.

What Breakthrough Therapy Designation Means?

The U.S. Food and Drug Administration’s Breakthrough Therapy Designation is reserved for therapies targeting serious or life-threatening diseases.

The program is designed to:

  • Accelerate clinical development
  • Provide intensive FDA guidance
  • Expedite regulatory review

This status is granted when early clinical evidence suggests a therapy could offer substantial improvement over existing treatments.

For Hemab, it signals strong regulatory support as the company advances sutacimig through clinical development.

The Unmet Need in Glanzmann Thrombasthenia

Glanzmann thrombasthenia is a rare inherited bleeding disorder characterized by defective platelet function.

Patients often experience:

  • Frequent spontaneous bleeding
  • Severe hemorrhages requiring hospitalization
  • Chronic disruptions to daily life

Data from the Glanzmann’s 360 (GT360) natural history study highlights the burden of the disease:

  • 88% of patients reported at least one bleeding episode in the previous week
  • 65% required a bleed-related hospital visit in the previous six months

The condition significantly affects quality of life:

  • Over 80% of patients miss school or work
  • More than 50% face travel restrictions
  • Social participation is often limited

Despite the severity of the disease, preventive treatment options remain extremely limited.

How Sutacimig Works?

Sutacimig (formerly HMB-001) is a subcutaneously administered bispecific antibody designed to improve clot formation in patients with GT.

The therapy uses a novel mechanism:

  • One arm binds and stabilizes Factor VIIa
  • The other arm binds to TLT‑1 on activated platelets

This dual binding mechanism is designed to:

  • Increase levels of endogenous Factor VIIa
  • Recruit the clotting factor directly to activated platelets
  • Promote hemostatic plug formation, helping stop bleeding

If successful, sutacimig could become the first prophylactic treatment specifically designed for Glanzmann thrombasthenia.

Clinical Trial Results Driving the FDA Decision

The Breakthrough Therapy Designation was supported by data from the Phase 2 multiple ascending dose portion of Hemab’s Phase 1/2 clinical trial (HMB-001-CL101).

Key findings from the study include:

  • Consistent reductions in bleeding events
  • Significant decreases in severe bleeds requiring intensive treatment

These severe cases often require interventions such as:

  • Recombinant Factor VIIa therapy
  • Platelet transfusions
  • Plasma or cryoprecipitate
  • Medical procedures

The results suggest sutacimig could meaningfully reduce bleeding burden in GT patients.

Additional Regulatory Designations

Beyond Breakthrough Therapy Designation, Sutacimig has received several other regulatory recognitions.

These include:

  • Fast Track Designation from the U.S. Food and Drug Administration
  • Orphan Drug Designation in the United States
  • Orphan medicinal product designation in the European Union
  • Innovative Licensing and Access Pathway (ILAP) designation from the Medicines and Healthcare products Regulatory Agency in the United Kingdom

Together, these designations aim to accelerate development and regulatory review for therapies addressing rare diseases.

Hemab’s Broader Strategy in Rare Blood Disorders

Hemab Therapeutics is a clinical-stage biotechnology company focused on prophylactic therapies for rare bleeding and thrombotic disorders.

The company operates from Cambridge, Massachusetts, and Copenhagen, Denmark, and is developing a pipeline targeting diseases with high unmet need.

Beyond Glanzmann thrombasthenia, its research efforts include treatments for:

  • Factor VII Deficiency
  • Von Willebrand Disease

The company’s goal is to shift treatment from reactive bleeding management to preventive care, offering patients more consistent protection and improved quality of life.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!